Time-averaged* parameters | Unadjusted model with ASDAS | Adjusted model with ASDAS† | Adjusted model with CRP† | Adjusted model with BASDAI† | Adjusted model with PG† | Adjusted model with BASDAI, PG and CRP† |
---|---|---|---|---|---|---|
Outcome: mSASSS progression by ≥2 points over 2 years | ||||||
ASDAS | 1.64 (1.03–2.62) | 1.80 (1.04–3.13) | – | – | – | – |
CRP | – | – | 1.04 (0.99–1.08) | – | – | 1.03 (0.98–1.07) |
BASDAI | – | – | – | 1.12 (0.87–1.45) | – | 0.79 (0.47–1.31) |
PG | – | – | – | – | 1.21 (0.97–1.51) | 1.42 (0.90–2.22) |
R2 of the model | 0.044 | 0.269 | 0.237 | 0.249 | 0.255 | 0.273 |
Outcome: syndesmophyte formation/progression over 2 years | ||||||
ASDAS | 2.62 (1.46–4.68) | 2.45 (1.26–4.77) | – | – | – | – |
CRP | – | – | 1.07 (1.01–1.13) | – | – | 1.06 (1.01–1.12) |
BASDAI | – | – | – | 1.25 (0.94–1.65) | – | 0.93 (0.51–1.70) |
PG | – | – | – | – | 1.30 (1.01–1.69) | 1.31 (0.76–2.27) |
R2 of the model | 0.129 | 0.367 | 0.317 | 0.353 | 0.334 | 0.376 |
*Over 2 years, up to five time-points.
†Adjusted for the presence of syndesmophytes at baseline, smoking status and NSAIDs intake score over 2 years.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; PG, patients global assessment of disease activity.